<DOC>
	<DOCNO>NCT00908011</DOCNO>
	<brief_summary>This study involve compare effectiveness treatment HIV positive patient may predispose heart attack stroke . The investigator evaluate effectiveness two drug , often prescribed doctor patient , lower cholesterol thereby make patient less less vulnerable suffer heart attack stroke . The investigator believe addition second drug , different class cholesterol lower medication , improve outcome patient lower cholesterol .</brief_summary>
	<brief_title>Addition Ezetimibe ( Ezetrol® ) Ongoing Therapy With Rosuvastatin ( Crestor® ) HIV Positive Patients Not Reaching Cholesterol Targets</brief_title>
	<detailed_description>This study seek determine whether HIV positive patient suboptimal lipid and/or reach specify lipid target benefit addition second lipid lower drug ( ezetimibe ) exist lipid lower therapy statin ( specifically rosuvastatin ) versus increase dose ongoing statin term improvement serum lipid parameter namely total cholesterol , LDL , HDL , triglycerides apolipoprotein B100 ( apoB ) , apolipoprotein A1 ( apoA1 ) , apoB/apoA1 ratio . The target population HIV+ patient hypercholesterolemia due highly active antiretroviral therapy , study randomize , parallel design . Sample size 50 patient already take 10 mg rosuvastatin reach lipid target receive either increase dose rosuvastatin ( 20mg ) receive 10mg ezetimibe addition ongoing rosuvastatin therapy . There 25 patient randomize group . At baseline serum sample obtain test serum triglyceride , total cholesterol , HDL , total cholesterol : HDL ratio , apoB , apoA1 , apoB/apoA1 ratio , liver transaminase ( AST ALT ) , CK , thyroid stimulate hormone , creatinine fast blood glucose . After 12 week therapy serum sample obtain test serum triglyceride , total cholesterol , HDL , total cholesterol : HDL ratio , apolipoprotein B100 , liver transaminase ( AST ALT ) , CK , thyroid stimulate hormone , creatinine fast blood glucose . The primary hypothesis combination rosuvastatin ezetimibe low serum apolipoprotein B100/apolipoprotein A1 ratio increase dose rosuvastatin alone , participant mixed dyslipidemia associate HIV therapy . Secondarily believe combination rosuvastatin ezetimibe low concentration serum cholesterol , LDL-cholesterol , triglyceride , apolipoprotein B100 C-reactive protein increase dose rosuvastatin alone , increase side effect administer participant mixed dyslipidemia associate HIV therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>HIV positive currently take 10mg rosuvastatin recent ( within three month ) fast lipid profile serum total cholesterol HDL ratio &gt; 5.0 Previous adverse reaction ezetimibe take ezetimibe within 30 day start study history vascular disease allergic reaction muscle problem take statin currently take lipid lower medication ( i.e . fibrates cholestyramine )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>HIV</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Statin</keyword>
	<keyword>Apolipoprotein B100/Apolipoprotein A1 ratio</keyword>
</DOC>